24 May 2013 - 24 May 2013 - US Baxter International (NYSE:BAX) and its partner Halozyme Therapeutics (NASDAQ:HALO) said that HyQvia (solution for subcutaneous use) has been approved in the EU as replacement therapy for adult patients with primary and secondary immunodeficiencies.

Baxter, which received the marketing authorisation, will launch HyQvia in select countries during the current year and plans to expand the launch to other EU member states in 2014.

Baxter's BioScience unit president Dr Ludwig Hantson said that the treatment gives patients with primary and secondary immunodeficiencies the ability to administer their treatment in a single subcutaneous site every three to four weeks.

HyQvia is comprised of human normal immunoglobulin (IGSC, 10%) and recombinant human hyaluronidase (licensed from Halozyme).